VANCOMYCIN

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category Free-form
ATC A07AA09 J01XA01 S01AA28
UNII 6Q205EH1VU
EPA CompTox DTXSID0042664

Structure

InChI Key MYPYJXKWCTUITO-LYRMYLQWSA-N
Smiles CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
InChI
InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C66H75Cl2N9O24
Molecular Weight 1449.27
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Bioactivity

Mechanism of Action Action Reference
Peptidoglycan inhibitor INHIBITOR FDA
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Protease Metallo protease Metallo protease MD clan Metallo protease M15 family Metallo protease M15D subfamily
- - - 62000 -
Enzyme Transferase
- 10000 - - -
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Adrenergic receptor
- - - 1000 -
Other cytosolic protein
- - - - 100
Secreted protein
- - 12000 - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC06 neurotransmitter transporter family
- - - 16 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters
- - - - 7
Unclassified protein
- - - - 30-30
Assay Description Organism Bioactivity Reference
In vitro binding affinity against alpha-2 adrenergic receptor of rat in presence of [3H]-RX 821002 radioligand None 125.89 nM
Binding affinity for human alpha-2 adrenergic receptor expressed in CHO cell Homo sapiens 50.12 nM
Antibacterial activity against gram positive bacteria Enterococcus faecalis was determined by twofold Micro-broth dilution assay Enterococcus faecalis 0.06 ug.mL-1
Antibacterial activity against gram negative bacteria Enterobacter aerogens was determined by twofold Micro-broth dilution assay Enterobacter aerogenes 250.0 ug.mL-1
Antibacterial activity against gram negative bacteria Escherichia coli was determined by twofold Micro-broth dilution assay Escherichia coli 250.0 ug.mL-1
The compound was tested for inhibitory activity against PGP30 bacterial cell wall biosynthesis Bacteria 5.2 ug.mL-1
In vitro binding affinity was determined against NA (noradrenaline) reuptake site of rat in presence of [3H]nisoxetine radioligand Rattus norvegicus 15.85 nM
In vitro binding affinity was determined against serotonin reuptake site of rat in presence of [3H]paroxetine radioligand Rattus norvegicus 50.12 nM
Antibacterial activity against gram negative bacteria Salmonella typhi was determined by twofold Micro-broth dilution assay Salmonella enterica subsp. enterica serovar Typhi 250.0 ug.mL-1
Antibacterial activity against gram negative bacteria Salmonella Typhimurium was determined by twofold Micro-broth dilution assay Salmonella enterica subsp. enterica serovar Typhimurium 250.0 ug.mL-1
Antibacterial activity against gram negative bacteria Shigella flexenerii was determined by twofold Micro-broth dilution assay Shigella flexneri 250.0 ug.mL-1
Antibacterial activity against gram positive bacteria Staphylococcus aureus was determined by twofold Micro-broth dilution assay Staphylococcus aureus 0.12 ug.mL-1
Concentration that inhibits 50% growth of methicillin resistant Staphylococcus aureus in the microdilution wells Staphylococcus aureus 839.0 nM
Inhibitory concentration required against cell wall synthesis in Staphylococcus aureus (MI246) Staphylococcus aureus 400.0 nM
Antibacterial activity against gram positive bacteria Staphylococcus epidermidis was determined by twofold Micro-broth dilution assay Staphylococcus epidermidis 0.3 ug.mL-1
Antibacterial activity against gram positive bacteria Streptococcus mutans was determined by twofold Micro-broth dilution assay Streptococcus mutans 0.12 ug.mL-1
Antibacterial activity against Salmonella Typhimurium after 16 to 20 hrs by broth microdilution method Salmonella enterica subsp. enterica serovar Typhimurium 50.0 %
Antibacterial activity against Staphylococcus epidermidis ATCC 14990 after 16 to 20 hrs by broth microdilution method Staphylococcus epidermidis 50.0 %
Antibacterial activity against Staphylococcus aureus ATCC 25923 after 16 to 20 hrs by broth microdilution method Staphylococcus aureus 100.0 %
Antibacterial activity against Bacillus subtilis ATCC 6633 after 16 to 20 hrs by broth microdilution method Bacillus subtilis 50.0 %
Antibacterial activity Listeria monocytogenes ATCC 15313 after 16 to 20 hrs by broth microdilution method Listeria monocytogenes 100.0 %
Antibacterial activity Streptococcus pyogenes ATCC 19615 after 16 to 20 hrs by broth microdilution method Streptococcus pyogenes 100.0 %
Antibacterial activity Streptococcus pneumoniae ATCC 49619 after 16 to 20 hrs by broth microdilution method Streptococcus pneumoniae 100.0 %
Antibacterial activity Enterococcus faecalis ATCC 29212 after 16 to 20 hrs by broth microdilution method Enterococcus faecalis 100.0 %
Antibacterial activity against Salmonella Typhimurium at 1 ug/ml after 16 to 20 hrs by broth microdilution method Salmonella enterica subsp. enterica serovar Typhimurium 50.0 %
Antibacterial activity against Staphylococcus epidermidis ATCC 14990 at 1 ug/ml after 16 to 20 hrs by broth microdilution method Staphylococcus epidermidis 50.0 %
Antibacterial activity against Staphylococcus aureus ATCC 25923 at 1 ug/ml after 16 to 20 hrs by broth microdilution method Staphylococcus aureus 100.0 %
Antibacterial activity against Bacillus subtilis ATCC 6633 at 1 ug/ml after 16 to 20 hrs by broth microdilution method Bacillus subtilis 50.0 %
Antibacterial activity Listeria monocytogenes ATCC 15313 at 1 ug/ml after 16 to 20 hrs by broth microdilution method Listeria monocytogenes 100.0 %
Antibacterial activity Streptococcus pyogenes ATCC 19615 at 1 ug/ml after 16 to 20 hrs by broth microdilution method Streptococcus pyogenes 100.0 %
Antibacterial activity Streptococcus pneumoniae ATCC 49619 at 1 ug/ml after 16 to 20 hrs by broth microdilution method Streptococcus pneumoniae 100.0 %
Antibacterial activity Enterococcus faecalis ATCC 29212 at 1 ug/ml after 16 to 20 hrs by broth microdilution method Enterococcus faecalis 100.0 %
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy Homo sapiens 7.1 %
Antibacterial activity against methicillin-resistant Staphylococcus aureus DSM 50128509 Staphylococcus aureus 0.14 ug.mL-1
Antibacterial activity against methicillin-resistant Staphylococcus epidermidis DSM 50160384 Staphylococcus epidermidis 0.14 ug.mL-1
Inhibition of lipid intermediate formation in methicillin susceptible Staphylococcus aureus RN4220 assessed as reduction in N-acetyl-D-[1-3H]glucosamine incorporation in crude assay system Staphylococcus aureus 180.0 ug.mL-1
Inhibition of methicillin susceptible Staphylococcus aureus RN4220 transglycosylase assessed as inhibition of peptidoglycan formation by crude assay Staphylococcus aureus 4.5 ug.mL-1
Inhibition of vancomycin A resistant Staphylococcus aureus isolate HIP11714 transglycosylase assessed as inhibition of peptidoglycan formation by crude assay Staphylococcus aureus 85.0 ug.mL-1
Antimicrobial activity against Enterococcus faecalis VanA assessed as growth inhibition at =<0.03 ug/ml by broth microdilution method Enterococcus faecalis 0.4 %
Antimicrobial activity against Enterococcus faecalis VanA assessed as growth inhibition at 0.06 ug/ml by broth microdilution method Enterococcus faecalis 0.9 %
Antimicrobial activity against Enterococcus faecalis VanA assessed as growth inhibition at 0.12 ug/ml by broth microdilution method Enterococcus faecalis 2.6 %
Antimicrobial activity against Enterococcus faecalis VanA assessed as growth inhibition at 0.25 ug/ml by broth microdilution method Enterococcus faecalis 3.9 %
Antimicrobial activity against Enterococcus faecalis VanA assessed as growth inhibition at 0.5 ug/ml by broth microdilution method Enterococcus faecalis 4.3 %
Antimicrobial activity against Enterococcus faecalis VanA assessed as growth inhibition at 1 ug/ml by broth microdilution method Enterococcus faecalis 4.3 %
Antimicrobial activity against Enterococcus faecalis VanA assessed as growth inhibition at 2 ug/ml by broth microdilution method Enterococcus faecalis 7.4 %
Antimicrobial activity against Enterococcus faecalis VanA assessed as growth inhibition at 4 ug/ml by broth microdilution method Enterococcus faecalis 14.8 %
Antimicrobial activity against Enterococcus faecalis VanB assessed as growth inhibition at =<0.03 ug/ml by broth microdilution method Enterococcus faecalis 9.5 %
Antimicrobial activity against Enterococcus faecalis VanB assessed as growth inhibition at 0.06 ug/ml by broth microdilution method Enterococcus faecalis 33.3 %
Antimicrobial activity against Enterococcus faecalis VanB assessed as growth inhibition at 0.12 ug/ml by broth microdilution method Enterococcus faecalis 70.2 %
Antimicrobial activity against Enterococcus faecalis VanB assessed as growth inhibition at 0.25 ug/ml by broth microdilution method Enterococcus faecalis 70.2 %
Antimicrobial activity against Enterococcus faecalis VanB assessed as growth inhibition at 0.5 ug/ml by broth microdilution method Enterococcus faecalis 75.0 %
Antimicrobial activity against Enterococcus faecalis VanB assessed as growth inhibition at 1 ug/ml by broth microdilution method Enterococcus faecalis 78.6 %
Antimicrobial activity against Enterococcus faecalis VanB assessed as growth inhibition at 2 ug/ml by broth microdilution method Enterococcus faecalis 85.7 %
Antimicrobial activity against Enterococcus faecalis VanB assessed as growth inhibition at 4 ug/ml by broth microdilution method Enterococcus faecalis 91.7 %
Antimicrobial activity against Enterococcus faecium VanA assessed as growth inhibition at =<0.03 ug/ml by broth microdilution method Enterococcus faecium 0.1 %
Antimicrobial activity against Enterococcus faecium VanA assessed as growth inhibition at 0.06 ug/ml by broth microdilution method Enterococcus faecium 0.3 %
Antimicrobial activity against Enterococcus faecium VanA assessed as growth inhibition at 0.12 ug/ml by broth microdilution method Enterococcus faecium 1.2 %
Antimicrobial activity against Enterococcus faecium VanA assessed as growth inhibition at 0.25 ug/ml by broth microdilution method Enterococcus faecium 3.1 %
Antimicrobial activity against Enterococcus faecium VanA assessed as growth inhibition at 0.5 ug/ml by broth microdilution method Enterococcus faecium 6.6 %
Antimicrobial activity against Enterococcus faecium VanA assessed as growth inhibition at 1 ug/ml by broth microdilution method Enterococcus faecium 11.5 %
Antimicrobial activity against Enterococcus faecium VanA assessed as growth inhibition at 2 ug/ml by broth microdilution method Enterococcus faecium 18.3 %
Antimicrobial activity against Enterococcus faecium VanA assessed as growth inhibition at 4 ug/ml by broth microdilution method Enterococcus faecium 33.1 %
Antimicrobial activity against Enterococcus faecium VanB assessed as growth inhibition at =<0.03 ug/ml by broth microdilution method Enterococcus faecium 26.1 %
Antimicrobial activity against Enterococcus faecium VanB assessed as growth inhibition at 0.06 ug/ml by broth microdilution method Enterococcus faecium 56.0 %
Antimicrobial activity against Enterococcus faecium VanB assessed as growth inhibition at 0.12 ug/ml by broth microdilution method Enterococcus faecium 71.6 %
Antimicrobial activity against Enterococcus faecium VanB assessed as growth inhibition at 0.25 ug/ml by broth microdilution method Enterococcus faecium 77.6 %
Antimicrobial activity against Enterococcus faecium VanB assessed as growth inhibition at 0.5 ug/ml by broth microdilution method Enterococcus faecium 85.1 %
Antimicrobial activity against Enterococcus faecium VanB assessed as growth inhibition at 1 ug/ml by broth microdilution method Enterococcus faecium 90.3 %
Antimicrobial activity against Enterococcus faecium VanB assessed as growth inhibition at 2 ug/ml by broth microdilution method Enterococcus faecium 94.0 %
Antimicrobial activity against Enterococcus faecium VanB assessed as growth inhibition at 4 ug/ml by broth microdilution method Enterococcus faecium 97.8 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group A' assessed as growth inhibition at =<0.03 ug/ml by broth microdilution method Streptococcus sp. 'group A' 98.8 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group A' assessed as growth inhibition at 0.06 ug/ml by broth microdilution method Streptococcus sp. 'group A' 99.9 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group A' assessed as growth inhibition at 0.12 ug/ml by broth microdilution method Streptococcus sp. 'group A' 99.9 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group A' assessed as growth inhibition at 0.25 ug/ml by broth microdilution method Streptococcus sp. 'group A' 100.0 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group B' assessed as growth inhibition at =<0.03 ug/ml by broth microdilution method Streptococcus sp. 'group B' 90.3 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group B' assessed as growth inhibition at 0.06 ug/ml by broth microdilution method Streptococcus sp. 'group B' 98.0 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group B' assessed as growth inhibition at 0.12 ug/ml by broth microdilution method Streptococcus sp. 'group B' 99.6 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group B' assessed as growth inhibition at 0.25 ug/ml by broth microdilution method Streptococcus sp. 'group B' 100.0 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group C' assessed as growth inhibition at =<0.03 ug/ml by broth microdilution method Streptococcus sp. 'group C' 99.4 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group C' assessed as growth inhibition at 0.06 ug/ml by broth microdilution method Streptococcus sp. 'group C' 100.0 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group G' assessed as growth inhibition at =<0.03 ug/ml by broth microdilution method Streptococcus sp. 'group G' 95.6 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group G' assessed as growth inhibition at 0.06 ug/ml by broth microdilution method Streptococcus sp. 'group G' 99.6 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group G' assessed as growth inhibition at 0.12 ug/ml by broth microdilution method Streptococcus sp. 'group G' 100.0 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. Group F assessed as growth inhibition at =<0.03 ug/ml by broth microdilution method Streptococcus sp. 97.1 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. Group F assessed as growth inhibition at 0.06 ug/ml by broth microdilution method Streptococcus sp. 97.1 %
Antimicrobial activity against Beta-hemolytic Streptococcus sp. Group F assessed as growth inhibition at 0.12 ug/ml by broth microdilution method Streptococcus sp. 100.0 %
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 12 hrs by Broth microdilution method Staphylococcus aureus 910.0 nM
Antibacterial activity against Staphylococcus aureus assessed as induction of bacterial membrane depolarization by flow cytometry Staphylococcus aureus 96.0 ug.mL-1
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 22 hrs by microbroth dilution antibiotic susceptibility assay Staphylococcus aureus 12.25 ug.mL-1
Inhibition of Staphylococcus aureus GTPase activity assessed as inorganic phosphate release upon GTP hydrolysis at 40 ug/ml preincubated for 10 mins before substrate addition measured after 2 hrs by malachite green based colorimetric analysis Staphylococcus aureus 99.7 %
Antibacterial activity against vancomycin-sensitive Staphylococcus aureus Newman assessed as inhibition of bacterial growth after 16 hrs Staphylococcus aureus 2.0 ug.mL-1
Antibacterial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 assessed as inhibition of bacterial growth after 16 hrs Staphylococcus aureus 8.0 ug.mL-1
Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as growth inhibition using fresh sample in DMSO by CLSI method Staphylococcus aureus 0.7 ug.mL-1
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as growth inhibition using fresh sample in DMSO by CLSI method Staphylococcus aureus 0.8 ug.mL-1
Antibacterial activity against methicillin-resistant Staphylococcus aureus EAMC30 assessed as growth inhibition using fresh sample in DMSO by CLSI method Staphylococcus aureus 0.2 ug.mL-1
Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as growth inhibition using fresh sample in DMSO by CLSI method Enterococcus faecalis ATCC 29212 1.0 ug.mL-1
Antibacterial activity against Enterococcus faecalis ATCC 51299 assessed as growth inhibition using fresh sample in DMSO by CLSI method Enterococcus faecalis 3.4 ug.mL-1
Inhibition of methicillin-resistant Staphylococcus aureus Mu50 TRAP assessed as potentiation of vancomycin-induced antibiofilm activity by measuring vancomycin-mediated reduction in colony forming units at 25 uM pretreated for 4 hrs prior to vancomycin addition measured after 20 hrs (Rvb = 30 +/- 14%) Staphylococcus aureus subsp. aureus Mu50 30.0 %
Inhibition of methicillin-resistant Staphylococcus aureus Mu50 TRAP assessed as potentiation of vancomycin-induced antibiofilm activity by measuring vancomycin-mediated reduction in colony forming units at 25 uM cotreated with vancomycin for 24 hrs (Rvb = 30 +/- 14%) Staphylococcus aureus subsp. aureus Mu50 30.0 %
Antibacterial activity against Staphylococcus aureus ATCC 25923 after 6 to 8 hrs by bacterial proliferation assay Staphylococcus aureus 670.0 nM
Antibacterial activity against Enterococcus faecium ATCC 19434 after 24 hrs by bacterial proliferation assay Enterococcus faecium 600.0 nM
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC BAA-44 after 6 to 8 hrs by bacterial proliferation assay Staphylococcus aureus 520.0 nM
Antibiofilm activity against Staphylococcus aureus Rosenbach ATCC 25923 after 24 hrs by crystal-violet based UV-Vis spectroscopy Staphylococcus aureus 540.0 nM
Bactericidal activity against planktonic growth of Staphylococcus aureus Rosenbach ATCC 25923 preincubated for 24 hrs followed by compound wash out and measured after 24 hrs Staphylococcus aureus 670.0 nM
Bactericidal activity against methicillin-resistant Staphylococcus aureus JCSC 4744 assessed as reduction in cell survival by measuring colony forming units at MIC measured within 4 hrs by time-kill assay relative to control Staphylococcus aureus 99.0 %
Antibiofilm activity against methicillin-resistant Staphylococcus aureus NRS384-USA300 clinical isolates assessed as inhibition of biofilm formation at 0.5 times MIC incubated for 24 hrs by crystal violet staining based spectrophotometric method relative to control Staphylococcus aureus 18.0 %
Antimicrobial activity against Candida albicans ATCC 90028 assessed as inhibition of microbial growth by CLSI based method Candida albicans 70.0 nM
Antimicrobial activity against Aspergillus fumigatus ATCC 90906 assessed as inhibition of microbial growth by CLSI based method Aspergillus fumigatus 70.0 nM
Antimicrobial activity against Cryptococcus neoformans ATCC 90113 assessed as inhibition of microbial growth by CLSI based method Cryptococcus neoformans 70.0 nM
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as inhibition of microbial growth by CLSI based method Staphylococcus aureus 0.4 nM
Antimicrobial activity against Escherichia coli ATCC 35218 assessed as inhibition of microbial growth by CLSI based method Escherichia coli 40.0 nM
Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of microbial growth by CLSI based method Pseudomonas aeruginosa 70.0 nM
Antibacterial activity against Enterococcus faecium ATCC 19434 incubated for 24 hrs by resazurin dye based fluorimetric assay Enterococcus faecium 500.0 nM
Antibiofilm activity against Staphylococcus aureus R3545 assessed as reduction in biofilm biomass at 32 ug/ml incubated for 24 hrs followed by plating on agar plate for 24 hrs by crystal violet staining assay relative to control Staphylococcus aureus 10.0 %
Antibiofilm activity against Staphylococcus aureus ATCC 33591 assessed as reduction in biofilm biomass at 32 ug/ml incubated for 24 hrs followed by plating on agar plate for 24 hrs by crystal violet staining assay relative to control Staphylococcus aureus 10.0 %
Antibacterial activity against Streptococcus pneumoniae ATCC 49617 Streptococcus pneumoniae 150.0 nM
Antibacterial activity against Streptococcus pneumoniae ATCC BAA1663 Streptococcus pneumoniae 130.0 nM
Antibacterial activity against Streptococcus pneumoniae ATCC 700904 Streptococcus pneumoniae 120.0 nM
Antimicrobial activity against Staphylococcus aureus ATCC 29213 assessed as inhibition of cell wall synthesis at 8 times MIC measured by liquid scintillation counter Staphylococcus aureus 87.3 %
Antibiofilm activity against Staphylococcus aureus ATCC 29213 assessed as reduction in preformed bacterial biofilm at 10XMIC incubated for 24 hrs by crystal violet staining based microtiter plate reader assay Staphylococcus aureus 7.7 %

Related Entries

Cross References

Resources Reference
ChEBI 28001
ChEMBL CHEMBL262777
DrugBank DB00512
DrugCentral 2807
FDA SRS 6Q205EH1VU
Human Metabolome Database HMDB0014653
Guide to Pharmacology 10932
PharmGKB PA451850
PubChem 14969
SureChEMBL SCHEMBL3177
CONTENTS